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Abstract: Reproductive function depends upon an operational hypothalamo–pituitary–gonadal
(HPG) axis. Due to its role in determining survival versus reproductive strategies, the HPG axis
is vulnerable to a diverse plethora of signals that ultimately manifest with Central Hypogonadism
(CH) in all its many guises. Acquired CH can result from any pituitary or hypothalamic lesion,
including its treatment (such as surgical resection and/or radiotherapy). The HPG axis is particularly
sensitive to the suppressive effects of hyperprolactinaemia that can occur for many reasons, including
prolactinomas, and as a side effect of certain drug therapies. Physiologically, prolactin (combined with
the suppressive effects of autonomic neural signals from suckling) plays a key role in suppressing
the gonadal axis and establishing temporary CH during lactation. Leptin is a further key endocrine
regulator of the HPG axis. During starvation, hypoleptinaemia (from diminished fat stores) results
in activation of hypothalamic agouti-related peptide neurons that have a dual purpose to enhance
appetite (important for survival) and concomitantly suppresses GnRH neurons via effects on neural
kisspeptin release. Obesity is associated with hyperleptinaemia and leptin resistance that may
also suppress the HPG axis. The suppressibility of the HPG axis also leaves it vulnerable to the
effects of external signals that include morphine, anabolic-androgenic steroids, physical trauma
and stress, all of which are relatively common causes of CH. Finally, the HPG axis is susceptible to
congenital malformations, with reports of mutations within >50 genes that manifest with congenital
CH, including Kallmann Syndrome associated with hyposmia or anosmia (reduction or loss of
the sense of smell due to the closely associated migration of GnRH with olfactory neurons during
embryogenesis). Analogous to the HPG axis itself, patients with CH are often vulnerable, and their
clinical management requires both sensitivity and empathy.
Keywords: hypogonadism; prolactin; leptin; Kallmann syndrome; stress
1. Introduction
Unlike other physiological and endocrine systems, survival is unshackled from the
function of the reproductive (hypothalamo–pituitary–gonadal (HPG)) axis. This unique
independence of the reproductive axis from survival prospects, positions the HPG axis as
an essential switch between survival and reproductive modes, a switch influenced by many
signals from diverse origins, and one that underlies the origin of central hypogonadism
(CH) in its many guises and clinical scenarios. Accordingly, the HPG axis in both sexes man-
ifests exquisite sensitivity to a great plethora of signals, undergoes suppression relatively
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easily, and acts as the body’s early warning system or “harbinger” of disease or distress.
From an evolutionary perspective, it is perhaps not surprising that such a scenario exists.
Many functions within the endocrine system (such as the hypothalamo–pituitary–adrenal
(HPA) [1] and thyroid axes [2] that regulate cortisol and thyroid hormone production,
respectively) form an essential and vital role for survival. Accordingly, the functioning
of such vital systems is typically robust, and is maintained despite the co-occurrence of
disease and distress (albeit with enhanced release of cortisol [3,4] and sometimes the sick
euthyroid syndrome [5]). Conversely, the HPG axis does not directly fulfil a vital role in
survival. Indeed, such independence of the HPG axis from a direct survival function occurs
naturally post-menopause [6]. Furthermore, reproduction is a facultative process. In times
of disease or distress, there is targeting of resources towards survival mode, and a shift
away from reproductive strategies [7]. Put simply, when survival is threatened, there is
usually suppression of the HPG axis and therefore diminished reproductive functioning
until such threats have receded.
Hypogonadism refers to a reduction or absence of sex hormone secretion or other
reproductive activity of the testes or ovaries. Hypogonadism is classified both clinically and
biochemically as primary hypogonadism (PH), reflecting defects at the level of the gonadal
tissue, and CH, reflecting defects within the central hypothalamo-pituitary reproductive
unit [8,9]. Biochemically, hypogonadism manifests with low serum levels of the sex steroids
(testosterone and oestradiol in men and women, respectively), and variable serum levels of
the gonadotrophins, Luteinising hormone (LH) and Follicle stimulating hormone (FSH),
according to the level of the defect [8]. The clinical manifestations of hypogonadism include
subfertility, reproductive dysfunction (anovulation and amenorrhoea in women; erectile
dysfunction and non-obstructive azoospermia in men [10]), and non-specific features such
as reduced vitality and wellbeing, physical weakness, bone mineral loss, and to some extent
emotional lability and reduced libido [11,12]. The vulnerability of the HPG axis renders CH
as a relatively common clinical scenario, especially in the context of obesity (predominantly
in males) and severe stress [13]. Indeed, it seems likely that CH is underdiagnosed,
given its frequent clinical presentation with non-specific features. Furthermore, it seems
likely that there is reduced awareness of CH as a clinical entity among non-specialist
healthcare professionals.
Although the causes of CH incorporate both congenital and acquired factors, its es-
sential feature is a lack of gonadal stimulation from the hypothalamo-pituitary axis [14].
Although CH underlies infertility in only 1–2% of male cases [15], these patients usually
respond relatively well to fertility treatments [10]. Acquired causes of CH mostly develop
during or after puberty, and can result from any type of pituitary [16,17] or hypothalamic
lesion (including prolactinomas and other pituitary neoplasms [18], craniopharyngiomas
and hypothalamic tumours [19]), and/or iatrogenically from the treatments of such le-
sions (including surgical resection and radiotherapy) [20]. Further acquired causes of
CH include pituitary trauma, the use of exogenous steroids, pituitary iron overload from
hereditary haemochromatosis or beta-thalassemia, and infiltrative conditions including
hypothalamic disorders [14,21,22]. Ultimately, these conditions of acquired CH impair the
function of gonadotroph cells within the anterior pituitary and/or reduce the function of
gonadotrophin releasing hormone (GnRH) neurons, and thereby reduce the release of FSH
and LH with consequent impaired spermatogenesis and testicular dysfunction in males,
and an absence of menstruation and hence sub-fertility in females [14,23]. The severity of
CH is commensurate with the severity of the underlying condition [21]. Congenital CH is
synonymous with idiopathic central hypogonadism (ICH), an umbrella term to classify the
failure of embryonic migration of GnRH neurons into the hypothalamus [21].
Here, we provide a narrative overview of the key mechanisms involved in CH. We
illustrate this with an overview of the genetics of ICH and implications for our under-
standing of the proper functioning and ontogeny of the HPG axis. We then discuss the
numerous mechanisms whereby multiple signals from diverse origins impact on the HPG
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axis (illustrated in Figure 1) to provide insight into the physiological functioning of the
HPG axis, and the numerous mechanisms that underlie the development of CH.
Figure 1. Overview of the main mechanisms that influence the gonadal axis. APG: Anterior pituitary gland; ARPN:
Agouti-related peptide neurons; CRH: Corticotrophin-releasing hormone; DOP: Dopamine; FSH: Follicle stimulating
hormone; GnRHN: Gonadotrophin releasing hormone neurons; GT: Gonadotroph cells; KPN: Kisspeptin neurons; LEP:
Leptin; LH: Luteinising hormone; LT: Lactotroph cells; PRL: Prolactin; SH: Sex hormone. Solid arrows denote stimulatory
effects (or hormonal release); Dotted (grey) arrows denote suppressive effects.
2. Methods
We performed a narrative literature review using PubMed. We used the search term
“central hypogonadism”, and prioritised published papers from the last 10 years (although
not exclusively), to enable modern insights from the latest published data.
3. The HPG Axis: Lessons from the Genetics of Idiopathic Central
Hypogonadism (ICH)
Considerable insight has been gained into the ontogeny, development and functioning
of the HPG axis through studying patients with genetic mutations that result in ICH.
The numerous identified gene mutations for ICH fall naturally into three main groups
that control: (i) neuronal differentiation and migration, (ii) GnRH secretion and (iii) the
development of GnRH receptors [21,24]. Each gene mutation has a variable effect on
GnRH neuronal migration or functioning that in turn determines the severity of the
clinical phenotype. This ranges from mild constitutional delay of puberty to more severe
phenotypes. It is beyond the scope of this concise review to provide a detailed exposition
of the genetics of ICH, recently outlined elsewhere [25]. Rather, we provide a summary of
the salient points, and develop this as a clinical guide to provide insight into the normal
development and functioning of the HPG axis, and the mechanisms that underlie the
development of CH.
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There is subdivision of ICH into Kallmann Syndrome (KS) with the co-presence of
olfactory dysfunction (anosmia or hyposmia), and normosmic ICH, although these sub-
divided entities likely sit on a spectrum within ICH as a whole [21,26]. KS is a genetically
heterogeneous disorder and underlies much CH globally [21,27]. In addition to anosmia or
hyposmia, patients with KS may also present with cleft lip and palate, sensorineural deficits,
motor impairment and renal agenesis [21]. The majority of hypothalamic GnRH neurons
have their origin within the olfactory placode at around the 5th week of gestation [25].
These GnRH neurons migrate alongside vomeronasal, olfactory and terminal nerves to
reach their destination in the infundibulum, mediobasal hypothalamus and periventricular
region [25,28]. The shared origin of nerves for olfaction and GnRH provides an explanation
for the association of ICH with olfactory impairment in around 50% of cases of ICH [25,29].
Although ANOS1 mutations in hemizygosity nearly always associate with a complete loss
of olfaction, those gene variants implicated in GnRH neuron migration and axon guidance,
and neurodevelopmental genes involved in the specification and differentiation of GnRH
neurons, are associated with a range of olfactory defects [25]. Due to their independence
from the co-migration of olfactory and GnRH neurons, gene variants that impair the action
of GnRH at the gonadotroph level, or are implicated in the activation of GnRH neurons or
the secretion of GnRH, do not associate with olfactory defects [25,30].
There is heterogeneity in the transmission of gene mutations for ICH that include
sporadic (the majority), autosomal dominant, autosomal recessive and X-linked inheri-
tance [21,31]. Overall, approximately half of cases of ICH have identified mutations within
around 50 genes, of which around 20 genes associate with KS [32]. Many of the genes
implicated in the development of ICH encode for G-protein-coupled receptors and (less
frequently) their cognate ligands [25]. ANOS1 (previously known as KAL1) was the first
gene identified with mutations that associate with KS [33], and occurs in ~10% of men with
KS (although implicated in 33–70% of familial cases) [21,34]. Mutations within ANOS1
transmit through familial X-linkage and influence early migration of GnRH neurons [35].
Conversely, mutations within FGFR1 (affecting ~12% of men with KS [36]) transmit through
an autosomal dominant mode, and together with mutations in PROK1 and PROK2 (G-
protein coupled receptors) influence both GnRH neuronal migration and olfactory bulb
development [37,38]. Other genes implicated in the pathogenesis of KS include GNRHR
that encodes the GnRH receptor [39], CHD7 [40] and FGF8 [41]. Patients harbouring delete-
rious variants of FGF8 have a greater prevalence of other congenital anomalies that include
dental agenesis, midline facial defects and digital bone abnormalities [25,42]. Furthermore,
sensorineural hearing loss occurs in 5–15% of patients with ICH (with a higher prevalence
in KS) [25,43], and is associated with mutations in ANOS1, SOX10 and CHD7 [25,44].
In a subset of patients, KS co-exists with other neuroendocrine disorders. It is likely
that the gene mutations that underlie these disorders influence common pathways early in
the process of embryogenesis, with multiple clinical manifestations [21,45]. Examples of
such gene mutations include those within SOX10 (KS in the context of Waardenburg-Shah
syndrome) [46], HESX1 (KS in the context of pituitary hormone deficiency and septo-optic
dysplasia) [47], NROB1 (ICH in the context of congenital adrenal dysplasia) [45] and LEP
(ICH in the context of obesity) [45].
Although substantial progress has been made in recent years regarding insights into
the genetic basis of ICH, various aspects remain uninvestigated, with apparent variability in
the penetrance and expressivity of gene variants that probably reflects oligogenicity of gene
variants (both known and unknown) [25]. Certain deleterious gene variants within FGFR1,
TUBB3 and CHD7 for example, may manifest with ICH in the heterozygous state [25].
Furthermore, in cases of homozygosity and compound heterozygosity in ICH, there are
commonly genotype–phenotype correlations. However, for many cases of gene variants
that underlie ICH, correlations between genotype and phenotype remain uncertain, and
it can be difficult to disentangle the relative effects of known and unknown genetic vari-
ants [25]. Although there has been a transformation of our knowledge and understanding
of the genetic aetiology of ICH in recent years, unfortunately the complexity of these mech-
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anisms outlined here limit the clinical utility and benefits of effective genetic counselling in
many cases of ICH.
4. Prolactin as a Natural Contraceptive
As outlined in the last section, ICH incorporates a whole spectrum of genetic anomalies
that provides insight into the ontogeny and functioning of the HPG axis, and through
dysfunction of GnRH neuronal regulation, the development of CH. In this section, we
consider the role of prolactin in the regulation of the HPG axis, and the mechanisms
whereby raised serum prolactin can result in the development of CH.
For many decades, there has been recognition of lactation as a natural contraceptive,
and a means of gaining central control of reproductive function [48]. Indeed globally, the
“lactational amenorrhoea method” remains important for contraception and family plan-
ning [49]. During suckling, afferent neural inputs pass from the nipple to the hypothalamus
via the spinal cord. These signals cause a local release of beta-endorphin that results in
suppression of GnRH secretion, with consequent suppression of gonadotrophin release and
arrested ovarian follicular development, ovulation and menstruation [49]. To complement
the direct suppression of GnRH secretion, the hypothalamic release of beta-endorphin
also suppresses the production of dopamine that in turn results in increased production
and secretion of prolactin from the anterior pituitary gland [49]. The mechanism(s) by
which raised serum prolactin mediates the suppression of gonadotrophin release during
lactation and suckling remains incompletely understood. However, recent evidence demon-
strates that prolactin inhibits the hypothalamic secretion of kisspeptin. The suppression of
kisspeptin release in turn results in reduced stimulation of GnRH release and development
of CH [50], a process which also involves endogenous endorphin or dynorphin [51]. It is
likely that kisspeptin neurons also contribute towards the feedback regulation of prolactin
secretion [50].
In women, lactation represents a natural form of CH, mediated through the release
of hypothalamic beta-endorphin with consequent disruption of the HPG axis through
both direct and indirect mechanisms as outlined, the latter implicating the release of
prolactin from the anterior pituitary gland. This is teleologically of value as it prevents
further conception while the infant is fully reliant on breast milk. However, raised serum
prolactin can occur outside of the context of lactation in both men and women, and exert
suppressive effects on the HPG axis with the induction of CH. Prolactin is one of the
apparent stress hormones. During stressful situations, serum levels of prolactin may
become elevated [52]. The direct inhibitory effect of raised prolactin on the HPG axis may
ensure optimal conditions for pregnancy through its avoidance during times of maternal
stress. However, it remains unclear as to why amenorrhoea persists later in lactation when
serum prolactin is only minimally elevated.
Raised serum prolactin can also occur following the development of a prolacti-
noma [53]. Clinically, prolactinomas often present with features of CH in both men and
women. However, compared with women, men with prolactinomas usually present clin-
ically with larger tumour size and a greater elevation of serum prolactin [54]. A likely
explanation for this sex difference in the clinical presentation of prolactinoma is that amen-
orrhoea serves as an early warning signal to women (particularly those with a history of
regular periods) that often prompts early medical attention. In men, there is no equivalent
to a monthly menstrual period, and therefore no aberration to any cyclical marker of HPG
functionality; in men, it is difficult to know when the reproductive “clock” stops ticking.
Conversely, prolactinoma-related reduced libido and erections will not necessarily prompt
early medical attention by men, and may go unnoticed or attributed to stress for example, or
even ignored due to embarrassment [55]. Consequently, men with prolactinomas typically
present late compared with women, and may even have developed some of the tumour
compressive features associated with pituitary macroadenomas, including bitemporal
hemianopia [56]. However, as microprolactinomas so rarely develop into macroadenomas,
this is unlikely to be the sole reason.
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In addition to prolactinomas, any hypothalamo-pituitary lesion (including non-functioning
pituitary tumours and craniopharyngiomas) can be associated with the development
of CH [17]. There are likely multiple mechanisms implicated that include the suppres-
sion of gonadotrophin release from the tumour itself, and “disconnection hyperprolacti-
naemia” [57]. There are suppressive effects of dopamine release on the pituitary lactotroph
cells, following its transit down the pituitary stalk [58]. Therefore, any lesion that impinges
on the pituitary stalk has the potential to disrupt dopamine signalling to the lactotroph
cells, manifesting with hyperprolactinaemia and thus a loss of stimulatory GnRH effect
with consequent CH. Furthermore, loss of pituitary stalk connectivity may directly im-
pair stimulation of gonadotrophin release and hypothalamic GnRH function. During the
clinical evaluation of hyperprolactinaemia, disconnection hyperprolactinaemia is gener-
ally associated with a serum level of prolactin <2000 mIU/L [59], although rarely it may
be higher.
A further clinically important aetiology of raised serum prolactin (and potential CH)
includes that related to drug side-effects (summarised in Table 1). During the clinical as-
sessment of patients with hyperprolactinaemia, it is essential to elicit a careful drug history
to exclude any potential side effects that may adversely affect the HPG axis and induce CH.
Most commonly, neuroleptic drug therapies associate with hyperprolactinaemia. These
include the classical anti-psychotic therapies (phenothiazines, butyrophenones and thiox-
anthenes) [60], and some atypical antipsychotic therapies such as risperidone [61]. Indeed,
with chronic usage of these anti-psychotic therapies, 40–90% of patients experience elevated
serum levels of prolactin, with clinical manifestations of amenorrhoea, galactorrhoea and
erectile dysfunction [61,62]. A number of the newer anti-depressant therapies can also
induce hyperprolactinaemia. These include selective serotonin reuptake inhibitors, sero-
tonin and noradrenaline reuptake inhibitors [61,63] and tricyclic antidepressants [61,64].
The prokinetic drugs metoclopramide and domperidone (through potent dopamine an-
tagonism) also commonly induce hyperprolactinaemia in a majority of patients taking
these therapies [61,65,66]. Finally, other drugs implicated in raised serum prolactin include
methyldopa [67], verapamil [68], opiates [69], alcohol, cocaine and marijuana [61,66]. Un-
like patients with prolactinomas (with levels of serum prolactin typically between 2000
and 5000 mIU/L for microprolactinoma, and >10,000 mIU/L for macroprolactinoma) [53],
patients with hyperprolactinaemia secondary to drug therapy typically only have mild
elevations of serum prolactin (usually, but not invariably, <2000 mIU/L). Following identi-
fication of a potential drug-induced cause of hyperprolactinaemia, discontinuation of the
suspected drug usually results in normalisation of serum prolactin levels and restoration
of a normally functioning HPG axis. Following discontinuation of oral antipsychotic drug
therapy, serum prolactin levels typically fall into the normal range within 2 to 4 days [61,70].
Persistent hyperprolactinaemia should prompt a search for alternative causes.
Table 1. Summary of drug causes of hyperprolactinaemia.













Reuptake Inhibitor Duloxetine, Venlafaxine
Tricyclic antidepressant Amitriptyline, Nortriptyline
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Table 1. Cont.




Anti-hypertensive Centrally-acting alpha-2adrenergic agonist Methyldopa
Anti-arrhythmic and
Anti-hypertensive Calcium-Channel Blocker Verapamil
Depressant
Analgesic Opiates
Recreational and “social” drug Alcohol
Stimulant Illicit drug Cocaine
Depressant, Stimulant and
Hallucinogen Recreational drug Marijuana
5. Leptin as a Gatekeeper between Survival and Reproduction
From an evolutionary perspective, both lactation and stress are potent suppressors
of the HPG axis. While the mediated influence of lactation on HPG axis suppression
occurs through the effects of prolactin release from the anterior pituitary, most forms of
stress suppress the HPG axis through mechanisms that are independent of an elevated
serum prolactin. However, other than stress, in addition to prolactin, leptin represents an
important determinant of HPG functioning in both men and women. Leptin acts within
a relatively narrow range of serum concentrations, any deviation from which can result
in compromise of HPG functioning [71]. In this section, we discuss the variable effects of
leptin on the HPG axis, acting as a gatekeeper according to its level within the serum.
5.1. Euleptinaemia and Hypoleptinaemia
Leptin is an adipokine released from adipose tissue depots commensurately with
the volume of adipose tissue [72]. As such, serum leptin serves as a useful biomarker of
adipose tissue reserve and provides an important peripheral signal to the hypothalamo-
pituitary unit that controls the HPG axis [73]. When adequate fat stores exist, providing
a propitious scenario for any putative pregnancy, serum levels of leptin are within the
normal range (euleptinaemia), and leptin acts as a hormone of permission [74]. In this
scenario of adequate fat reserves, leptin allows normal functioning of the reproductive axis
to ensue.
As the main hormone that communicates stored energy status to the rest of the
body, leptin has pleiotropic effects on numerous endocrine and neuronal systems. This
includes regulation of anterior pituitary hormones such as growth hormone, prolactin
and adrenocorticotrophic hormone (ACTH) [75]. However, leptin influences reproductive
function indirectly. Indeed, neurons that express GnRH do not actually express the leptin
receptor (OB-R) [76]. Rather, leptin acts on neurons within the hypothalamic ventral pre-
mamillary nucleus that express a dense concentration of leptin receptors [71], and that
project to hypothalamic regions that control reproductive function [77]. Leptin plays a key
role in appetite regulation and suppresses activity within the orexigenic agouti-related
peptide neurons. Agouti-related peptide suppresses the activity of kisspeptin neurons that
in turn reduces activity within GnRH neurons. Therefore, in euleptinaemia, suppression of
agouti-related peptide enables the release of GnRH and normal functioning of the HPG axis.
Conversely, in times of starvation when fat reserves are low, with consequent reduction in
the serum levels of leptin (hypoleptinaemia), there is activation of agouti-related peptide
neurons that in turn suppress activity within kisspeptin cells with consequent suppression
of GnRH release, reproductive function and leads to the development of CH [71]. Evidence
from a rodent-based study showed the mediation of the effects of leptin on the HPG axis
(including the kisspeptin system), at least in part, through effects on the nitrinergic system,
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especially within the arcuate nucleus [76]. The nitric oxide-containing cells surround the
GnRH neurons in a basket-like arrangement [78].
To summarise, leptin acts indirectly to control the activity of GnRH neurons (and
therefore reproductive functioning), via effects on the activity of kisspeptin neurons. Path-
ways upstream of kisspeptin neuron regulation implicate agouti-related peptide neurons
and the nitrinergic system [76]. Accordingly, the central control of the HPG axis functions
like a switch between survival and reproductive modes of physiology, with levels of leptin
as a major determinant of its status. Survival always takes precedence over reproduc-
tion. As such, the reproductive axis is particularly sensitive to any signalling of survival
threat, particularly starvation from a relative paucity of food availability and/or intake.
Mediated through effects on diminished serum levels of leptin from depleted fat stores,
any chronic energy deficiency can suppress the HPG axis. This includes anorexia nervosa,
lipodystrophies and relative energy deficiency in the context of sports, malnutrition and
starvation [79]. In one cross-sectional study of elite athletes and dancers, it was shown that
changes in both serum cortisol and insulin-like growth factor binding protein 1 (IGFBP-1)
accounted for the majority of the variance in menstrual cyclicity [80]. As an independent
predictor of amenorrhoea, IGFBP-1 may act as a peripheral signal to the central control of
the HPG axis, and mediate information on the availability of metabolic fuel for the control
of reproductive function (given the direct inverse regulation of IGFBP-1 levels by serum
insulin) [80]. In addition to excessive exercise, weight loss resulting from any chronic
and/or systemic illness (including malignancies and infectious diseases) can also result in
suppression of the HPG axis [79].
Appetite control is regulated within the hypothalamus, with agouti-related peptide as
the main orexigenic signal, and pro-opiomelanocortin (POMC) as a key anorexigenic signal.
It is interesting that in the context of hypoleptinaemia, the hypothalamic release of agouti-
related peptide (and concomitant reduced stimulation of hypothalamic POMC release)
appears to have a dual purpose to enhance appetite for food and suppress reproductive
function. Therefore, in the constant interplay and balance between survival (in this case,
the avoidance of starvation) and reproduction, agouti-related peptide appears to play a
central role.
5.2. Hyperleptinaemia
Weight gain with accumulation of excess adipose tissue and obesity associate with
elevated serum levels of leptin (hyperleptinaemia) [81,82]. Analogous to the context of
hypoleptinaemia, the development of hyperleptinaemia also results in suppression of
the HPG axis with resultant CH. However, unlike hypoleptinaemia, the mechanisms
that mediate the effects of hyperleptinaemia on suppression of the HPG axis remain
incompletely understood [83]. Obesity, particularly in the context of type 2 diabetes (T2D),
is related to the development of resistance to the effects of leptin. Effectively, obesity-
associated leptin resistance may have similar effects to hypoleptinaemia on the HPG axis,
with central suppression of GnRH secretion mediated through enhanced hypothalamic
release of agouti-related peptide [84]. In addition to central suppression of the HPG axis,
hyperleptinaemia also exerts direct negative effects on LH and hCG-stimulated testicular
androgen production and reduces the responsiveness of the testicular Leydig cells to
gonadotrophin stimulation [85]. Therefore, obesity-related hyperleptinaemia may suppress
the HPG axis at multiple levels both centrally and, at least in men, peripherally through a
reduced testicular response to gonadotrophins.
In male obesity, especially in the context of type 2 diabetes (T2D), numerous other
factors contribute towards the development of CH that include enhanced conversion of
testosterone to oestradiol within adipose tissue from enhanced aromatase activity [86], and
consequent central suppressive effects of oestradiol on the HPG axis. Furthermore, insulin
resistance, hyperinsulinaemia and associated inflammatory mediators may also suppress
HPG functioning [82]. One such inflammatory mediator, Interleukin-1β (IL-1β), is a potent
downregulator of the HPG axis during immune-inflammatory challenge in both men and
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women [87]. IL-1β suppresses the hypothalamic secretion of GnRH, with consequent
suppression of LH release from the anterior pituitary gland, and the development of CH.
In one study on explants of anterior pituitary gland from ewes, IL-1β also had direct effects
on pituitary gonadotroph cells, with suppression of GnRH-stimulated LH release and
LH-β gene expression [87]. Therefore, IL-1β may mediate the association of inflammatory
conditions (including the chronic inflammatory milieu of obesity) with suppressive effects
on the HPG axis [87]. In one study on men with features of the metabolic syndrome, there
was a significant inverse correlation between serum interleukin-6 (IL-6) and testosterone
levels [88]. Therefore, in addition to IL-1β, IL-6 probably also plays an important role
in the mediation of the suppressive effects of visceral obesity (and associated low-grade
inflammation) on the male HPG axis [88]. Finally, it is important to emphasise that in both
men and women, generalised inflammation and cytokine release likely contribute towards
the suppression of the HPG axis, even outside of the context of obesity and the metabolic
syndrome. For example, changes in inflammatory markers and serum testosterone are
likely causally linked in ageing men [89] and in patients with cancer-related cachexia [90].
To summarise this section, leptin appears to play a central role as a gatekeeper between
survival and reproductive modes of physiology. For optimal reproductive functioning,
there needs to be an ideal metabolic status that allows for euleptinaemia (serum leptin
levels within a narrow range). Chronic restriction of food intake with diminished fat stores
associates with hypoleptinaemia that switches off the reproductive axis, and concomitantly
enhances appetite for food (an important component of survival mode). Conversely, chronic
caloric excess with expanded adipose tissue depots associates with hyperleptinaemia and
leptin resistance, the reproductive and appetitive effects of which are similar to that which
occurs in the context of hypoleptinaemia due to diminished effectiveness of leptin on its
receptor, combined with the peripheral suppressive effects of hyperleptinaemia on the
testicular response to gonadotrophins. In this way, appetite for food and reproductive
functioning behave like two ends of a seesaw, with leptin and agouti-related peptide at
its fulcrum.
6. Signals from the Outside: Morphine, Anabolic-Androgenic Steroids, Physical
Trauma and Stress
The HPG axis is vulnerable to signals from diverse origins. Having explored the
endocrine contributors to HPG functioning (including the roles of prolactin and leptin),
in this section we consider the impact of external signals on the HPG axis. Numerous
environmental signals influence the proper functioning of the HPG axis. By definition
such signals originate from outside of the body. Furthermore, these signals have diverse
modalities that include both chemical and physical insults. We illustrate the mechanisms by
which external signals disrupt the HPG axis through the examples of morphine, anabolic-
androgenic steroids (AAS), physical trauma and stress.
6.1. Morphine
Human usage of opium dates back 8000 years. During the Renaissance, the creation
of various opium products resulted in common usage and subsequent addiction [91].
Morphine, the active ingredient of opium, was isolated chemically in the early 1800s by
Wilhelm Sertürner, with subsequent elucidation of its chemical and structural formula by
Sir Robert Robinson in the 1940s [91]. Plant-based extraction of morphine from the poppy
plant remains a major source of morphine-based therapies [91]. Currently, there is a stark
disparity and inequality in the global usage of opiates, with 80% of the world opiate supply
consumed by the United States (US) and 80% of the global population having no access
to opiates [92]. There was a sharp increase in opiate prescriptions and deaths from opiate
overuse in the 2000s, culminating in a global opiate crisis [92]. In a review of the literature,
Rose identified a peak in opiate analgesic prescribing and opiate overdose deaths in 2011,
with subsequent long-term decline [92]. There was a subsequent sharp increase in opiate
overdose in 2014, driven by illicit use of heroin and fentanyl. Currently, such illicit heroin
and fentanyl usage (rather than opiate prescribing) fuels the opiate crisis [92]. However,
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the widespread use of oxycodone, driven by pharma support, is also a major contributor to
the current opiate crisis.
The negative effects of opiates are legion, and their effects on male reproduction
are well known [93]. However, there seems to be a general lack of awareness among
healthcare professionals regarding the potential for CH in male users of opiates, and
this discussion is often absent during clinically-based treatments with opiate therapies,
including those discussions with patients [93]. In a recent systematic review and meta-
analysis of opiate effects on the HPG axis, de Vries and colleagues identified 52 studies from
the literature, with >18,400 subjects [94]. Indications for opiate usage (such as methadone
and morphine) included chronic pain and maintenance treatment for opiate addiction.
Overall, the prevalence of opiate-related CH was 63% (the vast majority, 99.5% being male
subjects), and opiate-related hypocortisolism occurred in 15% of subjects [94]. The authors
concluded that patients on chronic opiate therapy should undergo periodic evaluation of
the HPG and HPA axes [94]. In addition to the development of CH, exogenous opiates also
reduce semen quality and increase DNA fragmentation [93].
Although opiates exert their negative effects on the HPG axis through a variety of
mechanisms, their major mechanism of action is via the direct inhibition of GnRH re-
lease [95,96]. Opiate-related increases in prolactin release can also suppress gonadotrophin
production and secretion from the anterior pituitary gland [93]. There are also direct
negative effects of opiates on the testes, even in the context of well-maintained levels of an-
drogens. Endogenous production of opioids (within testicular Leydig and germ cells) exert
their paracrine effects through interaction with receptors throughout the testes (including
the regulation of androgen binding protein from effects on Sertoli cell receptors) [93]. There
are also effects of opioids on the expression of aromatase within the brain and testis [93]
that may further suppress the proper functioning of the HPG axis.
Given the prevalence of CH in male chronic users of opiates, with the majority having
some degree of CH, it seems surprising that this very common and potentially debilitating
side-effect of opiates is not more widely appreciated and discussed with male patients
prior to and at the time of prescription of opiate-based therapies. It is incumbent upon
healthcare professionals, especially those who prescribe opiates, to discuss the potential
(indeed likelihood in male patients) for CH development with patients, and the clinical
features of CH and the known adverse effects on testicular function and male fertility.
Furthermore, proper endocrine assessment of HPG functioning both prior to initiation of
opiates, and periodically whilst on opiates, is important to enable the early identification
and appropriate and timely management of opiate-related CH.
6.2. Anabolic-Androgenic Steroids (AAS)
AAS are testosterone derivatives typically used either recreationally or by athletes
to enhance strength and appearance and/or to improve athletic performance [97]. The
use of AAS is a relatively common cause of CH in clinical practice, the global lifetime
prevalence of AAS use being 6.4% and 1.6% for men and women, respectively [98]. How-
ever, despite the common usage of AAS, there is a limitation in our understanding of
the adverse effects of AAS and the mechanism(s) implicated through a lack of controlled
clinical trials in this field due to ethical constraints [98]. Therefore, much of our under-
standing derives from retrospective cohort studies and case reports. Such published data
reveal that the use and withdrawal of AAS commonly causes CH that may be profound
in its severity and frequently prolonged, and may cause substantial morbidity, including
potentially irreversible adverse effects on the HPG axis [97,99]. Rahnema and colleagues
conducted a review of the relevant literature and showed that symptoms of hypogonadism
in men who use AAS depends on the dose, duration and type of AAS used [100]. In
one systematic review and meta-analysis reported by Christou and colleagues, based on
>3800 primarily male subjects (>1700 AAS users) from >30 reported studies, most AAS users
had hypogonadism with persistently low serum levels of testosterone and gonadotrophins
lasting several weeks to months following discontinuation of AAS [97]. Furthermore, AAS
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associated with functional and structural changes in sperm, subfertility, gynaecomastia and
reduced testicular volume in men, and in women, clitoromegaly and menstrual irregulari-
ties [97]. In a further study on weight-lifters from the US, compared with non-AAS users
those who had formerly used AAS and had not been treated showed significantly smaller
testicular volumes and lower levels of serum testosterone that persisted in some cases for
>2 years [99]. Furthermore, this untreated group of former AAS users had significantly
lower scores of sexual desire, and in the group of former AAS users (both treated and
untreated), 29% had experienced major depressive episodes during the withdrawal of
AAS [99].
The mechanisms of CH associated with the use of AAS stems from negative feedback
in the central regulation of the HPG axis [98]. In women who use AAS, such HPG axis
dysregulation may manifest with disruption of ovarian function, acne, hirsutism and
deepening of the voice that may be irreversible [98]. Indeed, the clinical features of AAS in
women may masquerade as both the female athlete triad (menstrual disorders, low bone
mass and low energy intake) [98] and Polycystic Ovary Syndrome. This highlights the
importance of a careful history and examination in women who present with such common
clinical features to exclude any potential for use of AAS.
In addition to the adverse effects on the HPG axis, the use of AAS also associates
with cognitive and brain abnormalities similar to those in Alzheimer’s Disease. Supra-
physiological levels of androgens within the brain resulting from usage of AAS induce
androgenic abnormalities and oxidative stress that associate with changes in the expression
and activity of proteins that synthesize and eliminate β-amyloid and hyperphosphorylated
tau protein, with resultant accumulation of these abnormal proteins within the brain [101].
Such accumulation may accelerate through the concomitant usage of other psychoactive
substances, ultimately leading to an increased risk of the early development of dementia [101].
6.3. Physical Trauma
The hypothalamo-pituitary unit is particularly vulnerable to any physical trauma
to the head. Factors that may contribute towards this vulnerability include its anatom-
ical position at the base of the brain, and the portal circulation of the anterior pituitary,
enhancing its risk of injury from infarction following any trauma-related compromise
to its blood supply. Traumatic Brain Injury (TBI) is a relatively common cause of CH,
most commonly affecting younger adults under the age of 35 years. Pituitary dysfunc-
tion (including CH and other pituitary deficits such as hypothyroidism, hypocortisolism,
growth hormone deficiency and central diabetes insipidus) occurs in 20–40% of patients
following moderate and severe TBI in both the acute and chronic phases [102]. Although
the pathogenesis of hypopituitarism (including CH) following TBI remains incompletely
understood, hypotheses include direct injury from the primary mechanical event itself,
and secondary effects that include hypoxia, hypotension, changes in cerebral blood flow
and metabolism and raised intracranial pressure, that may ultimately induce ischaemic
adenohypophysial infarction [102]. In addition to acute TBI, even relatively minor but
repeated head injuries (such as through boxing, martial arts and football (“heading’ the
ball”)) can cause impairment of HPG function and the development of CH [103–107].
6.4. Stress
The term “stress” has multiple definitions across diverse fields. Even within the clinical
realm, “stress” is used as an umbrella term with multiple meanings. In this context, we use
the term “stress” to indicate a state of mental or emotional strain or tension resulting from
adverse or demanding circumstances. Stress often originates from the outside. Furthermore,
“adverse or demanding circumstances” are entirely subjective and likely to affect different
people in different ways [108,109]. Any change can have potential for eliciting a stress
response, even if personally perceived as having positive utility. We should not assume
therefore that stress only occurs following negative life events. Accordingly, stress within
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our busy, demanding, dynamic, unpredictable and highly changeable modern-day world,
is very common [110].
It is well established that stress can induce CH [111]. The clinical implications of stress-
induced CH include the development of amenorrhoea in girls, for example, in the context
of stress from examinations, and the onset of erectile dysfunction in men who experience
stress. As the existing literature on stress-induced CH appears orientated towards women,
we focus our discussion on “Stress-Amenorrhoea” (SA). In women, SA is common and
is thought to account for 15–48% of menstrual disorders [112,113]. Ultimately, SA ensues
from activation of multiple neural, metabolic and hormonal pathways that culminate in a
reduction of the pulsatile secretion of GnRH from hypothalamic neurons [111,112]. During
acute and chronic stress, there is activation of the sympathetic adreno-medullary and HPA
axes, respectively [114]. In addition to activation of the HPA axis, stress-related activation
of corticotrophin-releasing hormone (CRH) may also enhance the release of endogenous
opioid peptides and endorphins that in turn impair the pulsatile release of GnRH [112,115].
This is a mechanism of CH similar to the use of exogenous opiates [95]. Other mechanisms
that underlie SA include the impairment of kisspeptin-secreting neurons [112]. Interestingly,
although prolactin may be considered as a “stress hormone”, SA is probably not mediated
by hyperprolactinaemia. Indeed conversely, SA may associate with low levels of serum
prolactin due to stress-induced dopaminergic overtone [112,116]. Finally, we should
generally consider SA as a diagnosis of exclusion [112].
To summarise this section, the vulnerability of the HPG axis stems from its evolu-
tionary susceptibility to and necessity for suppressibility. Perhaps as a side-effect of the
hyper-responsiveness of the HPG axis to multiple internal (including neuronal and en-
docrine) signals, the HPG axis is also vulnerable to signals from the outside, such as the
use of opiates, AAS, physical trauma and stress. In one sense, the over-accommodating
nature of the HPG axis has left it vulnerable to being “gate-crashed” by unwanted guests.
7. To Treat or Not to Treat?
In any clinical scenario, the potential for CH exists. It is important to appreciate that the
identification of CH does not necessarily imply an urgent need for treatment with hormone
replacements [117]. Indeed, during acute illness or distress, the temporary occurrence of
CH may actually fulfil a protective role. It is apposite to consider the occurrence of CH in
its clinical scenario, including physiological CH such as during lactation or menopause. In
certain scenarios, such as CH from underweight and hypoleptinaemia, a clinical decision
is required regarding the need for hormone replacement. However, in these scenarios, it
is likely that hormone replacements are used for their non-reproductive benefits (such as
bone [11] and cardiovascular protection [118]), and may require adequate contraception
if pregnancy is considered harmful. A detailed discussion of treatment and management
options for CH is beyond the scope of this review and has been covered extensively recently
in an Endocrine Society Clinical Practice Guideline [117]. However, given the diversity and
complexity of the many clinical scenarios that manifest in CH, it is important to consider
each case individually. Furthermore, future research should explore options to complement
the administration of sex hormone replacement therapies for the treatment of CH, such as
the use of taurine [119].
Although the HPG axis controls reproductive function, it is important to consider the
non-reproductive effects of CH. As noted above, CH over the longer term can adversely
affect bone [11] and cardiovascular health [118], and result in reduced muscle mass and
physical strength [120]. Furthermore, CH can manifest with metabolic dysfunction [121],
reduced vitality, irritability and changes in cognition and emotional functioning. It is
important to raise awareness of these non-reproductive features of CH to ensure early
institution of appropriate investigations and diagnosis, and to enable timely referral to an
endocrine specialist. In women, the sudden loss of menstrual periods with the onset of
CH serves as an early warning. Unfortunately, there is no cyclical reproductive equiva-
lent in men. Therefore, CH can be more insidious in men, and may go unnoticed, or the
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non-reproductive features of CH attributed to something else such as stress. It is important
therefore, particularly in men and especially in the context of risk factors, to have a low
threshold for investigating CH and for prompt specialist referral when required. Thor-
ough investigation and management of CH should include consideration of its associated
sexual and reproductive dysfunctions with attendant emotional ramifications, and the
non-reproductive features of CH. Analogous to the HPG axis itself, the patient with CH is
often vulnerable.
8. Conclusions
To conclude, the HPG axis is vulnerable to numerous factors that include endocrine
inputs (effects of prolactin, leptin and β-endorphin); neural signals (such as occur during
suckling); inflammatory molecules (including interleukins and cytokines); stress; weight-
loss and energy-deficient states; hypothalamo-pituitary lesions (including disconnection
hyperprolactinaemia); and numerous external signals such as opiates, AAS, physical
trauma and stress. The complex ontogeny of the GnRH neurons with diverse genetic
regulation further enhances the vulnerability of the normal function of the HPG axis.
Finally, numerous drug therapies (outlined in Table 1) are associated with raised serum
prolactin with potential for the development of CH.
The facultative nature of the reproductive mode stems from a need to conserve
resources for survival in times of need, and to avoid the untimely allocation of resources for
reproduction at such times, that would further threaten survival. Indeed, in one reported
study on >21,600 couples married between 1860 and 1895 from the Utah Population
Database, increased number of offspring and reproductive rate actually correlated with
reduced parental survival, this correlation being significantly more pronounced for mothers
than for fathers [122]. Unsurprisingly, parental mortality resulted in reduced survival and
reproductive success of offspring [122]. These data highlight the fitness and survival
costs of reproduction within a human population, albeit from the 19th Century. Given
the implications of reproduction for survival, it is evolutionarily important to ensure
appropriate modes of survival versus reproduction at any given time. Accordingly, the
regulation of the HPG axis involves multiple inputs from a diverse array of origins, all of
which impact on its proper functioning. Ultimately, the HPG axis functions like a simple
switch: “off” for survival mode (denoting CH), and “on” for reproductive mode (denoting
normal reproductive functioning).
Finally, there is an important unmet clinical need for raised awareness of CH and its
numerous and varied causes amongst healthcare professionals. We need to ensure that we
always position the patient centrally in our clinical approach to CH, and to execute our
management both sensitively and with empathy.
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Kędzia, W.; Syrenicz, A. Functional hypothalamic amenorrhoea—Diagnostic challenges, monitoring, and treatment. Endokrynol.
Pol. 2015, 66, 252–260. [PubMed]
112. Lania, A.; Gianotti, L.; Gagliardi, I.; Bondanelli, M.; Vena, W.; Ambrosio, M.R. Functional hypothalamic and drug-induced
amenorrhea: An overview. J. Endocrinol. Investig. 2019, 42, 1001–1010. [CrossRef]
113. Gordon, C.M.; Ackerman, K.E.; Berga, S.L.; Kaplan, J.R.; Mastorakos, G.; Misra, M.; Murad, M.H.; Santoro, N.F.; Warren, M.P.
Functional hypothalamic amenorrhea: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2017, 102,
1413–1439. [CrossRef] [PubMed]
114. Schneiderman, N.; Ironson, G.; Siegel, S.D. Stress and health: Psychological, behavioral, and biological determinants. Annu. Rev.
Clin. Psychol. 2005, 1, 607–628. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 8217 18 of 18
115. Meczekalski, B.; Katulski, K.; Czyzyk, A.; Podfigurna-Stopa, A.; Maciejewska-Jeske, M. Functional hypothalamic amenorrhea and
its influence on women’s health. J. Endocrinol. Investig. 2014, 37, 1049–1056. [CrossRef] [PubMed]
116. Genazzani, A.D.; Chierchia, E.; Santagni, S.; Rattighieri, E.; Farinetti, A.; Lanzoni, C. Hypothalamic amenorrhea: From diagnosis
to therapeutical approach. Ann. Endocrinol. 2010, 71, 163–169. [CrossRef]
117. Bhasin, S.; Brito, J.P.; Cunningham, G.R.; Hayes, F.J.; Hodis, H.N.; Matsumoto, A.M.; Snyder, P.J.; Swerdloff, R.S.; Wu, F.C.;
Yialamas, M.A. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J. Clin.
Endocrinol. Metab. 2018, 103, 1715–1744. [CrossRef]
118. Elagizi, A.; Kohler, T.S.; Lavie, C.J. Testosterone and cardiovascular health. Mayo Clin. Proc. 2018, 93, 83–100. [CrossRef]
119. Yang, J.; Wu, G.; Feng, Y.; Lv, Q.; Lin, S.; Hu, J. Effects of taurine on male reproduction in rats of different ages. J. Biomed. Sci. 2010,
17 (Suppl. 1), S9. [CrossRef]
120. McKee, A.; Morley, J.E.; Matsumoto, A.M.; Vinik, A. Sarcopenia: An Endocrine disorder? Endocr. Pract. 2017, 23, 1140–1149.
[CrossRef] [PubMed]
121. Dwyer, A.A.; Quinton, R. The metabolic syndrome in central hypogonadotrophic hypogonadism. Front. Horm. Res. 2018, 49,
156–169.
122. Penn, D.J.; Smith, K.R. Differential fitness costs of reproduction between the sexes. Proc. Natl. Acad. Sci. USA 2007, 104, 553–558.
[CrossRef]
